Close menu




December 8th, 2025 | 07:15 CET

Leveraging AI revenue potential: The master plan from Novo Nordisk, Aspermont, and Deutsche Telekom

  • bigdata
  • Digitization
  • Telecommunications
  • Biotechnology
  • AI
Photo credits: pixabay.com

Artificial intelligence is permeating the economy and creating an unprecedented productivity boost. Efficiency gains of 25% in manufacturing and savings of one trillion dollars by 2030 in supply chains are just the beginning. This growth potential of up to 0.8 percentage points per year leverages the profitability of pioneers and clearly separates them from the rest of the market. Who are the pioneers who are already applying this disruptive force today and will translate it into concrete profits in the future? Three companies are leading the way: Novo Nordisk, Aspermont, and Deutsche Telekom.

time to read: 4 minutes | Author: Armin Schulz
ISIN: NOVO NORDISK A/S | DK0062498333 , ASPERMONT LTD | AU000000ASP3 , DT.TELEKOM AG NA | DE0005557508

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Novo Nordisk – AI as the secret engine in the pharmaceutical laboratory

    Novo Nordisk consistently uses artificial intelligence to accelerate its research. Algorithms comb through genetic data, model new molecules, and optimize the clinical trial process. This integration is intended to shorten development times and increase the hit rate for new active ingredients. Strategic partnerships, such as with NVIDIA, provide the necessary computing power. For investors, this is a long-term efficiency lever. A faster and more accurate pipeline will enable more promising candidates to reach advanced stages in the future and secure a development lead in core areas such as diabetes and obesity.

    In early December, Novo Nordisk closed a deal worth up to USD 2.1 billion for Zaltenibart, a Phase 2 drug candidate. The drug targets rare blood and kidney diseases. The transaction underscores the Company's commitment to strategically supplement its portfolio through external innovation. Such acquisitions are a key component of its growth strategy beyond its currently strong core business with GLP-1 drugs. They show that Novo is prepared to invest in promising therapeutic areas that could open up new sources of revenue in the long term.

    In mid-December, two announcements attracted attention. First, the Company unsuccessfully completed a clinical trial with an oral semaglutide for Alzheimer's disease. While this is a setback for this indication, it does not affect the central growth driver of GLP-1 therapies. At the same time, Novo announced the launch of Ozempic in India. This move into one of the world's largest markets underlines the Company's global expansion strategy. The goal is clear: to expand its market-dominating position in diabetes and obesity therapy in emerging economies as well, and to establish it before generics enter the market. The stock is currently available for EUR 41.00.

    Aspermont – From publisher to data powerhouse in the commodities sector

    The days when media companies only printed are long gone. The Australian company Aspermont is currently demonstrating how historical industry knowledge can be turned into a sustainable data model. In recent years, the former print provider has transformed itself from a traditional specialist publisher for mining and energy with more than 100 years of history into a digital platform. Its latest strategic coup is the introduction of the AI-powered data intelligence platform "Mining IQ". It analyses project risks, ESG data, and market sentiment in real time, providing a genuine decision-making tool for the volatile commodities industry. This step makes the Company the architect of a networked, data-driven industry economy.

    The financial figures underscore the success of the transformation. As the Company announced at the end of October, recurring revenue rose to AUD 11.2 million in the fourth quarter of 2025, the 37th consecutive quarter of growth. Total revenue from continuing operations increased by 5% to AUD 4.7 million. A milestone was the first corporate contract for Mining IQ with mining giant Rio Tinto, worth AUD 550,000. This partnership not only validates the product but also marks the entry into a scalable SaaS business with attractive margins. Backed by a recently completed institutional capital placement, the Company is now well-positioned to translate this momentum into profitable growth.

    At the same time, the Nexus marketing segment is running at full speed. On November 5, Aspermont announced a new government partnership with the Timor-Leste Mineral Authority. Nexus is developing tailor-made campaigns to position the country as a mining location. These high-profile collaborations, alongside others with Saudi Arabia and BHP, demonstrate how the Company is translating its editorial credibility and global network into profitable services. The transition from publisher to data and solutions provider appears to have been successful and is creating a significantly broader revenue base. The stock is currently trading at AUD 0.007.

    Deutsche Telekom – AI as a growth driver

    Deutsche Telekom is pursuing a new strategy. Artificial intelligence is set to become a key growth driver. Instead of focusing exclusively on traditional telecommunications services, as it did in the past, the group is now investing heavily in high-performance data centers, which provide the computing power needed for machine learning. This strategic realignment is aimed at generating higher margins. Through partnerships, for example, with a leading US chip manufacturer, the Company is building a powerful European AI platform. This offering, which could meet with high demand right now, comes at the right time, as many companies are looking for local alternatives to the American hyperscalers.

    The IT subsidiary T-Systems is responsible for the operational implementation. An existing data center in Munich is being expanded into a so-called "AI factory" and will house tens of thousands of high-performance GPUs. Starting in 2026, customers from industry and research will be able to flexibly rent this computing power without having to invest in expensive hardware themselves. The data will remain under German jurisdiction, a strong argument in terms of data protection and digital sovereignty. The first major customers are already testing applications such as digital twins.

    For investors, the math is simple. This business promises significantly better margins than the traditional mobile communications business, supported by long-term contracts and additional services. The group is leveraging its existing infrastructure and can thus scale comparatively agilely. The growth potential is considerable, driven by the explosive demand for AI computing power in Europe. In the long term, this diversification could stabilize revenue streams and increase return on investment by supplementing cyclical telecom revenues with recurring cloud and AI contracts. The share price is currently trading at around EUR 27.37.


    These three companies demonstrate how AI is driving tomorrow's revenue growth. Novo Nordisk is leveraging AI to accelerate pharmaceutical research and expand its valuable drug pipeline. Aspermont is transforming historical industry knowledge with platforms such as Mining IQ into scalable data solutions for the commodities sector. With its "AI factory," Deutsche Telekom is building a cloud and infrastructure division with high margins. Together, these companies prove that AI is not an abstract concept, but an operational lever for greater efficiency, new business models, and sustainable competitive advantages.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author



    Related comments:

    Commented by Nico Popp on December 9th, 2025 | 07:05 CET

    Attacking the fuel that feeds tumors: Why Roche, Pfizer, and Vidac Pharma are redefining oncology

    • Biotechnology
    • Pharma
    • Biotech
    • Cancer
    • Innovations

    Modern cancer therapy is no longer about blunt-force attacks, but rather precise, targeted interventions. While oncology in recent decades has been dominated by non-specific cell toxins, today's research resembles surgical intervention in the biological software of a disease. Industry heavyweights, Roche and Pfizer, are securing their market positions with gigantic portfolios of immunotherapies. But away from the corporate headquarters of Basel and New York, agile biotech pioneers are working on approaches that attack the very foundation of cancer cells: their energy supply. Those who pull the plug on cancer cells could be among the big winners in the biotech sector in 2026.

    Read

    Commented by Fabian Lorenz on December 8th, 2025 | 07:15 CET

    RENK better than HENSOLDT? Risk at NOVO NORDISK! Billion-dollar opportunity with RZOLV Technologies!?

    • Technology
    • Mining
    • Sustainability
    • Gold
    • Biotechnology
    • Defense

    Is RENK's stock better than Hensoldt's? That is what analysts are saying. According to them, the transmission specialist is attractively valued at the current level. Hensoldt, on the other hand, is having problems converting its order backlog into revenue growth, leading to a significant reduction in its price target. In contrast, RZOLV Technologies shares have enormous upside potential. The Company aims to replace a toxic chemical used in gold extraction, thereby opening up a billion-dollar market. Development is nearly complete, and patents have been filed. In just a few months, RZOLV could become a hot takeover candidate. Meanwhile, takeovers currently appear to be a way for Novo Nordisk to replenish its drug pipeline, with the Danish company taking risks worth billions - Pfizer, take note.

    Read

    Commented by Nico Popp on December 4th, 2025 | 06:55 CET

    How suppliers like Aspermont, CATL, and Continental turn the world's complexity into profit

    • Batteries
    • Technology
    • Digitization
    • bigdata
    • Automotive
    • manufacturing

    "During a gold rush, don't sell shovels - sell treasure maps." In a world driven by technological disruption, geopolitical tensions, and the trend toward decarbonization, investors need to think one step ahead. Often, it is not the end manufacturers who benefit most, but the specialized suppliers and service providers operating behind the scenes. They take the complexity off their customers' hands – whether it is building an electric vehicle, optimizing tyre compounds, or deciding where to build the next billion-dollar mine. Those who understand this principle will find exciting options on the stock market right now. We present three companies.

    Read